Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns

FOSTER CITY, Calif.--(BUSINESS WIRE)--Dec. 21, 2021-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the use of injectable lenacapavir in borosilicate vials in all...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials